We are live on !
Find out more
Daniel Loeb Third Point
AUM
$4.68B
Turnover
50%
1-Year Est. Return
37.3%
Daniel Loeb is the founder of Third Point, an event-driven and activist-oriented hedge fund. He is known for pointed letters to management teams, catalyst-driven investing, and a flexible mandate across equities and credit. Loeb’s campaigns and portfolio shifts regularly generate attention beyond specialist hedge fund circles.
This Fund
S&P 500
This Quarter Est. Return
+8.12%
1 Year Est. Return
+37.3%
3 Year Est. Return
+159.49%
5 Year Est. Return
+329.12%
10 Year Est. Return
+1,791.94%
AUM
$11.5B
AUM Growth
+$1.01B
(+9.6%)
Cap. Flow
+$441M
Cap. Flow % of AUM
Cap. Flow %
3.83%
Top 10 Holdings %
Top 10 Hldgs %
62.83%
Holding
49
New
9
Increased
10
Reduced
10
Closed
11
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$265M |
| 2 |
Humana
HUM
|
+$243M |
| 3 |
Alibaba
BABA
|
+$241M |
| 4 |
Meta Platforms (Facebook)
META
|
+$211M |
| 5 |
STJ
St Jude Medical
STJ
|
+$210M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$272M |
| 2 |
Lowe's Companies
LOW
|
+$238M |
| 3 |
Sealed Air
SEE
|
+$207M |
| 4 |
Yum! Brands
YUM
|
+$178M |
| 5 |
EMC CORPORATION
EMC
|
+$163M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.09% |
| 2 | Materials | 14.4% |
| 3 | Communication Services | 13.16% |
| 4 | Consumer Staples | 9.68% |
| 5 | Industrials | 8.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Baxter International
BAX
$13.1B
| $2.47B | 21.48% |
51,901,767
| – | – |
2015 Q2
5 quarters
|
|
2
DuPont de Nemours
DD
$17.6B
| $1.04B | 9.01% |
7,897,622
| – | – |
2013 Q4
11 quarters
|
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $872M | 7.58% |
3,785,000
-1,115,000
| -23% | -$272M |
2014 Q1
10 quarters
|
|
|
4
Meta Platforms (Facebook)
META
$1.81T
| $699M | 6.08% |
5,450,000
+1,700,000
| +45% | +$211M |
2016 Q2
1 quarter
|
|
5
Alphabet (Google) Class A
GOOGL
$4.17T
| $442M | 3.84% |
11,000,000
+3,000,000
| +38% | +$117M |
2016 Q1
2 quarters
|
|
|
MON
6
DELISTED
Monsanto Co
MON
| $378M | 3.29% |
3,700,000
+1,700,000
| +85% | +$178M |
2016 Q2
1 quarter
|
|
7
Constellation Brands
STZ
$22.2B
| $366M | 3.18% |
2,200,000
+200,000
| +10% | +$33M |
2013 Q2
13 quarters
|
|
8
Danaher
DHR
$161B
| $353M | 3.07% |
5,076,000
-652,153
| -11% | -$46.2M |
2015 Q3
4 quarters
|
|
9
TransDigm Group
TDG
$63B
| $327M | 2.84% |
1,131,000
| – | – |
2016 Q1
2 quarters
|
|
|
10
Apple
AAPL
$5.01T
| $283M | 2.46% |
+10,000,000
| New | +$265M |
2016 Q3
0 quarters
|
|
|
11
Alibaba
BABA
$271B
| $275M | 2.39% |
+2,600,000
| New | +$241M |
2016 Q3
0 quarters
|
|
12
Charter Communications
CHTR
$12.6B
| $270M | 2.35% |
1,000,000
-450,000
| -31% | -$114M |
2016 Q2
1 quarter
|
|
|
BID
13
DELISTED
Sotheby's
BID
| $253M | 2.2% |
6,661,604
+679
| +0% | +$24K |
2013 Q2
13 quarters
|
|
14
S&P Global
SPGI
$127B
| $253M | 2.2% |
2,000,000
+400,000
| +25% | +$48M |
2016 Q2
1 quarter
|
|
|
15
Humana
HUM
$49.6B
| $248M | 2.15% |
+1,400,000
| New | +$243M |
2016 Q3
0 quarters
|
|
16
Sherwin-Williams
SHW
$81.4B
| $242M | 2.1% |
2,625,000
+525,000
| +25% | +$50.9M |
2016 Q2
1 quarter
|
|
17
Chubb
CB
$139B
| $226M | 1.97% |
1,800,000
-550,000
| -23% | -$69.8M |
2015 Q4
3 quarters
|
|
18
AB InBev
BUD
$163B
| $210M | 1.83% |
1,600,000
-300,000
| -16% | -$37.9M |
2014 Q1
10 quarters
|
|
19
General Dynamics
GD
$93.1B
| $209M | 1.82% |
1,350,000
+994,900
| +280% | +$148M |
2016 Q2
1 quarter
|
|
|
STJ
20
DELISTED
St Jude Medical
STJ
| $207M | 1.8% |
+2,600,000
| New | +$210M |
2016 Q3
0 quarters
|
|
21
Conagra Brands
CAG
$6.91B
| $200M | 1.74% |
+5,461,250
| New | +$196M |
2016 Q3
0 quarters
|
|
22
Molson Coors Class B
TAP
$7.37B
| $187M | 1.62% |
1,700,000
+700,000
| +70% | +$71.1M |
2015 Q2
5 quarters
|
|
23
Mohawk Industries
MHK
$8.15B
| $180M | 1.57% |
900,000
-600,000
| -40% | -$123M |
2014 Q4
7 quarters
|
|
|
SHPG
24
DELISTED
Shire pic
SHPG
| $174M | 1.52% |
900,000
-50,000
| -5% | -$9.8M |
2016 Q2
1 quarter
|
|
25
Visa
V
$756B
| $174M | 1.51% |
+2,100,000
| New | +$168M |
2016 Q3
0 quarters
|
|
Similar funds
TCIM
Daniel Loeb's Q3 2016 Portfolio in Review
As of Q3 2016, Daniel Loeb held 49 positions worth $11.5B, up 9.6% from $10.5B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Daniel Loeb deployed $441M of net new capital in Q3 2016, opening 9 new positions and adding to 10 existing holdings. Its largest new stake was Apple: 10,000,000 shares worth $283M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Materials and Communication Services.
On the sell side, the largest reduction was Allergan plc, an estimated $272M trimmed.
- Daniel Loeb's largest Q3 2016 buy was Apple: 10,000,000 shares worth $283M.
- Daniel Loeb added most to Meta Platforms (Facebook) in Q3 2016, an estimated $211M increase.
- Daniel Loeb's biggest Q3 2016 reduction was Allergan plc, cutting an estimated $272M.
- Daniel Loeb fully exited Lowe's Companies in Q3 2016, selling an estimated $238M.
- Daniel Loeb's ten largest holdings make up 63% of its $11.5B portfolio in Q3 2016.
- Daniel Loeb opened 9 new positions and closed 11 in Q3 2016.
- Daniel Loeb's portfolio value rose 9.6% quarter-over-quarter to $11.5B.
Based on Third Point's 13F filing for Q3 2016, filed 10 Nov 2016.